Bibliography
- BENOIST M, BARELLIER MT, GAUTIER P, HODARAM M, ALIX M: Venous thromboembolic disease of the elderly. Detection and treatment. J. Mal. Vasc. (1994) 19(4) :289–293.
- Progress in the treatment of stroke: good news from the clinic- new therapeutic strategies. Drugs and Market Development (1997) 8(4) :83–91.
- ARDISSIMO D, MERLINI PA, ARIENS R, et al.: Tissue factor antigen and activity in human coronary plaques. Lancet (1997) 349:769–771.
- HARKER LA, HANSON SR, KELLY AB: Antithrombotic strategies targeting thrombin activity, thrombin receptors and thrombin generation. Thromb. Haemost. (1997) 78(1) :736.
- SWAINGER C: New antiplatelet agents. Pharmaprojects Magazine (April 1997) :17–20.
- COLLEN D: Thrombolytic therapy. Thromb. Haemost. (1997) 78(1) :742–746.
- Recent advances in thrombolytic drugs. Drug and Market Development (1997) 8(4)77–80.
- BADIMON JJ, MEYER B, FEIGEN LP, et al.: Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. Eur. J. Clin. Invest. (1997) 27(7) :568–574.
- FRANSSEN J, SALEMINK I, WILLEMS GM, et al.: Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor. Biochem. J. (1997) 323:33–37.
- GRUBER A, HANSON SR, KELLY AB, et al.: Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation (1982) 82:578–585.
- HIRSH J, SIRAGUSA S, COSMI B, GINSBERG S: Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb. Haemost. (1995) 74(1) :360–363.
- THE EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. New Engl. J. Med. (1994) 330:956–961.
- FAREED J, HOPPENSTEAD D, JESKE W, CLARIZIO R, WALENGA JM: Low molecularweight heparins: a developmental perspective. Exp. Opin. Invest. Drugs (1997) 6(6)705–732.